Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 85.5% in January

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 164,900 shares, an increase of 85.5% from the December 31st total of 88,900 shares. Based on an average daily trading volume, of 1,790,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.1% of the company’s shares are short sold.

Virax Biolabs Group Stock Down 1.4 %

VRAX stock traded down $0.03 during midday trading on Wednesday, hitting $2.02. The stock had a trading volume of 29,843 shares, compared to its average volume of 384,417. The company’s 50-day moving average price is $2.04 and its 200 day moving average price is $2.21. Virax Biolabs Group has a 12-month low of $0.60 and a 12-month high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.